Tools and methods for providing assurance of clonality for legacy cell lines

Taymar Hartman, Abbvie Biotherapeutics Inc., Redwood City, CA, United States Louise Almond, Allergan Biologics Ltd, Liverpool, United Kingdom Jennitte Stevens, Amgen Inc, Thousand Oaks, CA United States Sam Yaghmour, Amgen Inc, Thousand Oaks, CA United States John Thrift, Bayer HealthCare LLC, Berkeley, CA, United States Juhi Ohja, Bayer HealthCare LLC, Berkeley, CA, United States Paul Wu, Bayer HealthCare LLC, Berkeley, CA, United States Christina Alves, Biogen Inc, Cambridge, MA, United States David Shaw, Genentech Inc, South San Francisco, CA, United States Mike Laird, Genentech Inc, South San Francisco, CA, United States Robyn Emmins, GSK, King of Prussia, PA, United States; Stevenage, United Kingdom Yuan Zhu, GSK, King of Prussia, PA, United States; Stevenage, United Kingdom Ren Liu, Merck & Co., Inc., Kenilworth, NJ, United States Zhimei Du, Merck & Co., Inc., Kenilworth, NJ, United States Rolf Koehler, Novartis Pharma AG, Basel, Switzerland Thomas Jostock, Novartis Pharma AG, Basel, Switzerland Karin Anderson, Pfizer Inc, Andover MA, United States Howard Clarke, Seattle Genetics Inc, Bothell, WA, United States Chris Campbell, Takeda Pharmaceuticals, Cambridge MA, United States